OpenLB
Open Library of Bioscience
Advanced Search
In vivo (Athens, Greece)
2024 May-Jun;38 (3): 1271-1277.

The Impact of Cryopreservation on Hematopoietic Stem Cell Engraftment and Post-transplant Outcome During the COVID-19 Pandemic.

Anna Strzelec, Natalia Gawlik-Rzemieniewska, Anna Klima, Karolina Panek, Grzegorz Helbig
Author Information
  1. Anna Strzelec: Faculty of Medicine in Katowice, Medical University of Silesia, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland anna.agata.strzelec@gmail.com.
  2. Natalia Gawlik-Rzemieniewska: Faculty of Medicine in Katowice, Medical University of Silesia, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland.
  3. Anna Klima: Faculty of Medicine in Katowice, Medical University of Silesia, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland.
  4. Karolina Panek: Faculty of Medicine in Katowice, Medical University of Silesia, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland.
  5. Grzegorz Helbig: Faculty of Medicine in Katowice, Medical University of Silesia, Department of Hematology and Bone Marrow Transplantation, Katowice, Poland.
PMID: 38688614 DOI: 10.21873/invivo.13565

Abstract

BACKGROUND/AIM: The COVID-19 pandemic has had a significant impact on the current management of allotransplanted patients in whom fresh hematopoietic stem cells (HSCs) were replaced by cryopreserved ones. The aim of the study was to determine the efficacy and safety of cryopreserved HSCs when compared with the fresh ones.
patients AND METHODS: A retrospective analysis of 254 allogeneic stem cell transplantations (HSCT) procedures performed between 2020-2021 included the following donors: matched related (MRD; n=68), matched unrelated (MUD; n=148) and haploidentical (HID; n=38). 50% of patients (non-cryo group) received fresh grafts, whereas the remaining patients (cryo group) were transplanted with cryopreserved cells.
RESULTS: No differences in terms of median days to neutrophil [MRD/MUD/HID cryo- and non-cryo groups: 17 vs. 16 (p=0.27), 19 vs. 18 (p=0.83), 22 vs. 22 (p=0.83) days, respectively] and platelet [MRD/MUD/HID cryo- and non-cryo groups: 14 vs. 14 (p=0.25), 17 vs. 17 (p=0.33), 21 vs. 19 (p=0.36) days, respectively] engraftments were demonstrated. Among MUD graft recipients, platelet engraftment rates were 81% in the cryo- and 96% in the non-cryo group (p=0.01). OS rates were comparable at 1 year after HSCT between MRD/MUD/HID cryo- and non-cryo groups: 53% vs. 60% (p=0.54), 60% vs. 66% (p=0.5), 50% vs. 41% (p=0.56), respectively.
CONCLUSION: During the COVID-19 pandemic, cryopreserved HSCs did not have a negative impact on median engraftment time and OS when compared to fresh HSCs. In the MUD group, platelet engraftment rate was lower in cryopreserved HSC recipients.

Keywords

Allogeneic hematopoietic stem cell transplantation cryopreservation engraftment survival

References

  1. Transplant Cell Ther. 2021 Dec;27(12):1022.e1-1022.e6 [PMID: 34571211]
  2. Bone Marrow Transplant. 2018 Mar;53(3):274-280 [PMID: 29269805]
  3. Blood Adv. 2018 Dec 26;2(24):3590-3601 [PMID: 30563883]
  4. Cell Transplant. 2021 Jan-Dec;30:963689721999617 [PMID: 33757335]
  5. Fertil Steril. 2022 Mar;117(3):469-476 [PMID: 35219471]
  6. Bone Marrow Transplant. 2018 May;53(5):521-534 [PMID: 29335625]
  7. Transplant Cell Ther. 2021 Aug;27(8):664.e1-664.e6 [PMID: 33964514]
  8. JCI Insight. 2020 May 7;5(9): [PMID: 32376800]
  9. Bone Marrow Transplant. 2021 Mar;56(3):532-535 [PMID: 32528122]
  10. Transplant Cell Ther. 2024 Feb;30(2):210.e1-210.e14 [PMID: 38043802]
  11. Bone Marrow Transplant. 2023 Dec;58(12):1348-1356 [PMID: 37673982]
  12. Curr Stem Cell Rep. 2022;8(2):72-92 [PMID: 35502223]
  13. Bone Marrow Transplant. 2019 Jan;54(1):138-141 [PMID: 30108325]
  14. F1000Res. 2018 Nov 5;7:1746 [PMID: 31489176]
  15. Blood Adv. 2021 Dec 14;5(23):5140-5149 [PMID: 34581754]
  16. Transfus Apher Sci. 2022 Dec;61(6):103495 [PMID: 35780074]
  17. J Hosp Infect. 2023 Sep;139:11-22 [PMID: 37308062]
  18. Transfus Apher Sci. 2023 Dec;62(6):103821 [PMID: 37775358]
  19. Cytotherapy. 2016 Oct;18(10):1325-31 [PMID: 27491794]
  20. Am J Blood Res. 2021 Oct 15;11(5):544-563 [PMID: 34824887]
  21. Transfus Apher Sci. 2020 Apr;59(2):102753 [PMID: 32305212]
  22. Biol Blood Marrow Transplant. 2019 Jul;25(7):1441-1449 [PMID: 30794929]
  23. Biol Blood Marrow Transplant. 2019 Jul;25(7):1465-1471 [PMID: 30928627]
  24. Transfus Apher Sci. 2016 Jun;54(3):324-36 [PMID: 27211042]
  25. Acta Biomed. 2020 Mar 19;91(1):157-160 [PMID: 32191675]
  26. Transfus Apher Sci. 2020 Aug;59(4):102742 [PMID: 32171686]
  27. Expert Rev Hematol. 2021 Jan;14(1):79-96 [PMID: 33297779]
  28. Transfus Med Hemother. 2023 Sep 15;50(5):417-427 [PMID: 37899990]
  29. J Clin Med. 2022 Jul 15;11(14): [PMID: 35887878]
  30. Cells. 2021 Jul 20;10(7): [PMID: 34360005]
  31. Immunohorizons. 2021 Aug 25;5(8):711-720 [PMID: 34433626]
  32. Transfus Apher Sci. 2018 Apr;57(2):163-167 [PMID: 29724627]
  33. Leukemia. 2022 Jun;36(6):1467-1480 [PMID: 35488021]
  34. J Hematol Oncol. 2021 Oct 14;14(1):168 [PMID: 34649563]
  35. Transplant Cell Ther. 2021 Mar;27(3):270.e1-270.e6 [PMID: 33781537]
  36. Exp Clin Transplant. 2022 Mar;20(3):237-245 [PMID: 33641657]

MeSH Term

Humans
Cryopreservation
COVID-19
Hematopoietic Stem Cell Transplantation
Male
Female
Adult
Middle Aged
Hematopoietic Stem Cells
SARS-CoV-2
Retrospective Studies
Graft Survival
Transplantation, Homologous
Treatment Outcome
Aged
Pandemics
Graft vs Host Disease
Young Adult
Adolescent
Journal Article

Word Cloud

Created with Highcharts 10.0.0p=0vscryopreservednon-cryofreshHSCsgroupcryo-engraftmentCOVID-19patientsstemMUDdaysgroups:17plateletpandemicimpacthematopoieticcellsonescomparedcellHSCTmatched50%median[MRD/MUD/HID198322respectively]14recipientsratesOS60%BACKGROUND/AIM:significantcurrentmanagementallotransplantedreplacedaimstudydetermineefficacysafetyPATIENTSANDMETHODS:retrospectiveanalysis254allogeneictransplantationsproceduresperformed2020-2021includedfollowingdonors:relatedMRDn=68unrelatedn=148haploidenticalHIDn=38receivedgraftswhereasremainingcryotransplantedRESULTS:differencestermsneutrophil16271825332136engraftmentsdemonstratedAmonggraft81%96%01comparable1yearMRD/MUD/HID53%5466%541%56respectivelyCONCLUSION:negativetimeratelowerHSCImpactCryopreservationHematopoieticStemCellEngraftmentPost-transplantOutcomePandemicAllogeneictransplantationcryopreservationsurvival

Similar Articles

Cited By

No available data.